Status: Recommended | ||
Ambrisentan (Volibris®) is recommended as an option for use within NHS Wales for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue. Ambrisentan (Volibris®) is recommended as an option for use within NHS Wales, for the treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO FC II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease. |
||
|
||
Medicine details |
||
Medicine name | ambrisentan (Volibris®) | |
Formulation | 2.5 mg, 5 mg, 10 mg film-coated tablet | |
Reference number | 4819 | |
Indication | Treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease |
|
Company | GlaxoSmithKline UK | |
BNF chapter | Cardiovascular system | |
Submission type | Licence extension for paediatric use | |
Status | Recommended | |
Advice number | 2022 | |
AWMSG meeting date | 18/10/2022 | |
Date of issue | 07/11/2022 | |
Further information This advice incorporates and replaces the AWMSG recommendation for ambrisentan (Volibris®) for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. (advice number 2508, originally published 2009). The additional sentence ‘Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease’ is added to reflect the change in the wording of the licensed indication. |